SynthesisFrontiers in oncology2020
Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.
Synthesis in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- The effect ofFrontiers in endocrinology · 2025Pooled it
- Treatment strategies for unilateral papillary thyroid carcinoma with ipsilateral cervical lymph node metastasis: a narrative review.Gland surgery · 2026Review
- Validating the 2022 WHO classification in thyroid carcinomas: Prospective evidence for predicting iodine resistance.Histopathology · 2026Article
- Aggressive follicular cell derived thyroid carcinoma: what do you need from the pathologist.Virchows Archiv : an international journal of pathology · 2026Review
- Evaluation of BRAF V600E and TERT mutation analysis in differential thyroid cancers.Updates in surgery · 2026Article
- A histo-clinical score to predict evolution to radioactive iodine-refractory of the follicular cell-derived thyroid carcinoma (PREDIRAIR): a single-centre, prospective, cohort study.EClinicalMedicine · 2026Article
- Dyna-RR-DTC model: integrating clinicopathological features with dynamic indicators to predict radioiodine-refractory differentiated thyroid cancer risk.Annals of nuclear medicine · 2026Article
- Association between clinical and pathological factors and risk of radioiodine refractory in patients with differentiated thyroid carcinoma.Frontiers in endocrinology · 2026Article
- Two-year dynamic risk stratification and adjuvant radioiodine efficacy in initial non-distant metastatic papillary thyroid carcinoma harboring TERT promoter mutations.Frontiers in oncology · 2026Article
- Encapsulated neoplasms of the thyroid gland.Virchows Archiv : an international journal of pathology · 2026Review
- Identifying risk factors associated with refractoriness to radioiodine therapy in differentiated thyroid cancer.Archives of endocrinology and metabolism · 2025Article
- Gene Expression Analysis of Papillary Thyroid Carcinoma With Lymph Node Metastasis and Radioiodine Refractivity.Cureus · 2025Article
- Associations between pathological features and radioactive iodine-refractory recurrent papillary thyroid carcinoma: with mutation analysis using recurrent samples.BMC endocrine disorders · 2025Article
- The ability of anexelekto (AXL) expression and TERT promoter mutation to predict radioiodine-refractory differentiated thyroid carcinoma.Diagnostic pathology · 2025Article
- The value of preoperative molecular testing in the management of Bethesda V and Bethesda VI thyroid tumors.Hormones (Athens, Greece) · 2025Review
- The Efficacy and Safety of Anlotinib in the Treatment of Thyroid Cancer: A Systematic Review.Journal of clinical medicine · 2025Review
- Lymphatic metastasis of papillary thyroid carcinoma: mechanism and clinicopathological physiology.Frontiers in endocrinology · 2025Review
- The utility of quantitativeAsia Oceania journal of nuclear medicine & biology · 2025Article
- High risk factors, molecular features and clinical management for radioactive iodine-refractory differentiated thyroid carcinoma.Frontiers in oncology · 2025Review
- The right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC).Journal of clinical & translational endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.